Inspiration
Drug discovery is a long, expensive, and failure-prone process — with nearly 90% of drugs failing during clinical trials due to poor predictions or incomplete understanding of patient biology.
We were inspired by two facts:
- Digital Twins have the potential to simulate real patients for virtual drug testing, but they require massive, high-quality, multi-modal data.
- AGI (Artificial General Intelligence) can not only understand biomedical context but also generate missing data and integrate diverse datasets.
The idea of combining these two — to bridge data gaps and make drug discovery faster, safer, and more personalized — drove our project.
---JupyterNotebook
What it does
Our solution uses AGI to fill in missing biomedical data, then feeds this enriched data into a Digital Twin engine to simulate a patient’s biological systems.
With these personalized Digital Twins, we can:
- Virtually test how a patient might react to a new drug.
- Predict both intended effects and possible side effects.
- Reduce the number of risky and expensive human trials.
How we built it
- Data Gathering – We collected partial patient data from open biomedical datasets.
- AGI Module – We used advanced AGI models (like GPT-4, Gemini) to:
- Understand the biomedical context.
- Predict missing patient parameters (e.g., metabolic profiles).
- Understand the biomedical context.
- Digital Twin Framework – We integrated this completed dataset into a patient simulation model.
- Virtual Drug Testing – We ran simulations for drug efficacy and safety.
- Visualization & Analysis – Output results for clinicians and researchers to interpret.
Challenges we ran into
- Data Privacy & Regulations – Strict laws (HIPAA, GDPR) make it hard to use real-world medical data.
- Synthetic Data Ethics – Gaining trust that AGI-generated data is accurate and ethically acceptable.
- Model Accuracy – Ensuring that AGI predictions match real biological outcomes.
- Integration Complexity – Combining genomics, EHR, and clinical trial data in a unified format.
Accomplishments that we're proud of
- Designed the conceptual framework for integrating AGI with Digital Twin models in drug discovery.
- Developed a high-level algorithmic approach outlining how models can leverage transfer learning and continuous learning for improved biomedical predictions.
- Mapped out the data flow and integration strategy for combining incomplete patient data, AGI-generated synthetic data, and digital twin simulations.
- Defined the potential impact and scalability of the approach for multiple diseases beyond the initial target case.
What we learned
- AGI can play a transformative role in biomedical data completion and integration.
- Digital Twins can significantly improve early drug testing when provided with accurate, diverse datasets.
- The combination of AGI + Digital Twin can offer personalized healthcare solutions at scale.
- Ethical and regulatory compliance is as important as technical accuracy in healthcare AI projects.
What's next for AGI for Solving Data Gaps in Digital Twin Drug Discovery
- Integration with Real Hospital Systems – Directly pull and update patient data securely.
- Wearable & IoT Device Connectivity – Use real-time health data for continuously updated Digital Twins.
- Custom Medical AGI Models – Train domain-specific AGI to further improve prediction accuracy.
- Expansion to Vaccine Development – Apply the same approach to infectious disease modeling.
- Regulatory Collaboration – Work with medical boards and data protection agencies to ensure safe deployment.
Log in or sign up for Devpost to join the conversation.